Nulojix Related Published Studies
Well-designed clinical trials possibly related to Nulojix (Belatacept)
Comparison of alternative primary outcome measures for use in lupus nephritis
clinical trials. [2013]
A randomized controlled trial to evaluate inhibition of T-cell costimulation in
allergen-induced airway inflammation. [2013]
Evaluation of abatacept administered subcutaneously in adults with active
rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity,
efficacy and safety (phase Iiib ALLOW study). [2012]
Improvements in participation in usual daily activities in patients with
rheumatoid arthritis treated with abatacept. [2011]
Investigation into the impact of abatacept on sleep quality in patients with
rheumatoid arthritis, and the validity of the MOS-Sleep questionnaire Sleep
Disturbance Scale. [2010]
Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment. [2010]
Indirect comparison of tocilizumab and other biologic agents in patients with
rheumatoid arthritis and inadequate response to disease-modifying antirheumatic
drugs. [2010]
Sequential use of biologic therapy in rheumatoid arthritis. [2010]
Impact of T-cell costimulation modulation in patients with undifferentiated
inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging
study of abatacept (the ADJUST trial). [2010]
Safety and efficacy of the selective costimulation modulator abatacept in
patients with rheumatoid arthritis receiving background methotrexate: a 5-year
extended phase IIB study. [2009]
Clinical efficacy and safety of abatacept in methotrexate-naive patients with
early rheumatoid arthritis and poor prognostic factors. [2009]
Validation of the 28-joint Disease Activity Score (DAS28) and European League
Against Rheumatism response criteria based on C-reactive protein against disease
progression in patients with rheumatoid arthritis, and comparison with the DAS28
based on erythrocyte sedimentation rate. [2009]
Decreased external home help use with improved clinical status in rheumatoid
arthritis: an exploratory analysis of the Abatacept in Inadequate responders to
Methotrexate (AIM) trial. [2008]
Treatment impact on estimated medical expenditure and job loss likelihood in
rheumatoid arthritis: re-examining quality of life outcomes from a randomized
placebo-controlled clinical trial with abatacept. [2008]
Results of a two-year followup study of patients with rheumatoid arthritis who
received a combination of abatacept and methotrexate. [2008]
Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III,
multi-centre, randomised, double-blind, placebo-controlled study in patients with
rheumatoid arthritis and an inadequate response to methotrexate. [2008]
Safety of T-cell co-stimulation modulation with abatacept in patients with
rheumatoid arthritis. [2007]
Abatacept improves both the physical and mental health of patients with
rheumatoid arthritis who have inadequate response to methotrexate treatment. [2007]
Selective costimulation modulation using abatacept in patients with active
rheumatoid arthritis while receiving etanercept: a randomised clinical trial. [2007]
Abatacept. [2006]
Treatment of rheumatoid arthritis patients with abatacept and methotrexate
significantly improved health-related quality of life. [2006]
Improved health-related quality of life for rheumatoid arthritis patients treated
with abatacept who have inadequate response to anti-TNF therapy in a
double-blind, placebo-controlled, multicentre randomized clinical trial. [2006]
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha
inhibition. [2005]
Treatment of rheumatoid arthritis with the selective costimulation modulator
abatacept: twelve-month results of a phase iib, double-blind, randomized,
placebo-controlled trial. [2005]
Treatment of rheumatoid arthritis by selective inhibition of T-cell activation
with fusion protein CTLA4Ig. [2003]
Costimulatory blockade in patients with rheumatoid arthritis: a pilot,
dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig
and LEA29Y eighty-five days after the first infusion. [2002]
Other research related to Nulojix (Belatacept)
Belatacept for kidney transplant recipients. [2014]
Transcriptional profiling of belatacept and calcineurin inhibitor therapy in
renal allograft recipients. [2014]
Prospective monitoring of cytomegalovirus, Epstein-Barr virus, BK virus, and JC
virus infections on belatacept therapy after a kidney transplant. [2014]
Renal transplantation using belatacept without maintenance steroids or
calcineurin inhibitors. [2014]
Belatacept-versus cyclosporine-based immunosuppression in renal transplant
recipients with pre-existing diabetes. [2011]
A phase III study of belatacept-based immunosuppression regimens versus
cyclosporine in renal transplant recipients (BENEFIT study). [2010]
Technology evaluation: Belatacept, Bristol-Myers Squibb. [2005]
Costimulation blockade with belatacept in renal transplantation. [2005]
Other possibly related research studies
Risk of malignancies in patients with rheumatoid arthritis treated with biologic
therapy: a meta-analysis. [2012]
Abatacept for lupus nephritis: alternative definitions of complete response
support conflicting conclusions. [2012]
My treatment approach to rheumatoid arthritis. [2012]
Indirect treatment comparison of abatacept with methotrexate versus other
biologic agents for active rheumatoid arthritis despite methotrexate therapy in
the United kingdom. [2012]
Abatacept for Crohn's disease and ulcerative colitis. [2012]
Biologic rheumatoid arthritis therapies: do we need more comparative
effectiveness data? [2012]
Model-based determination of abatacept exposure in support of the recommended
dose for Japanese rheumatoid arthritis patients. [2011]
A mixed treatment comparison of the short-term efficacy of biologic disease
modifying anti-rheumatic drugs in established rheumatoid arthritis. [2011]
Adverse effects of biologics: a network meta-analysis and Cochrane overview. [2011]
Effectiveness of biologic therapies for rheumatoid arthritis: an indirect
comparisons approach. [2011]
Cost-effectiveness of biologics in polyarticular-course juvenile idiopathic
arthritis patients unresponsive to disease-modifying antirheumatic drugs. [2011]
Comparative effectiveness of rheumatoid arthritis therapies. [2010]
Evaluation of disease activity assessments in patients with rheumatoid arthritis
and an inadequate response to anti-TNF therapy: analyses of abatacept clinical
trial data. [2010]
Strategies after the failure of the first anti-tumor necrosis factor alpha agent
in rheumatoid arthritis. [2010]
Efficacy of initial methotrexate monotherapy versus combination therapy with a
biological agent in early rheumatoid arthritis: a meta-analysis of clinical and
radiographic remission. [2010]
Abatacept for rheumatoid arthritis: a Cochrane systematic review. [2010]
Abatacept for rheumatoid arthritis. [2009]
Newer biological agents in the treatment of rheumatoid arthritis: do the benefits
outweigh the risks? [2009]
[Biological agents]. [Article in Japanese] [2009]
[Efficacy of new biologics on bone destruction in rheumatoid arthritis]. [Article in Japanese] [2009]
[A novel treatment option in rheumatoid arthritis: abatacept, a selective modulator of T-cell co-stimulation] [2009]
Validation of a simple activity participation measure for rheumatoid arthritis
clinical trials. [2009]
The 6-month safety and efficacy of abatacept in patients with rheumatoid
arthritis who underwent a washout after anti-tumour necrosis factor therapy or
were directly switched to abatacept: the ARRIVE trial. [2009]
The effect of costimulatory and interleukin 2 receptor blockade on regulatory T
cells in renal transplantation. [2008]
Selective costimulation modulation with abatacept: a look at quality-of-life
outcomes in patients with rheumatoid arthritis. [2009]
Improved health-related quality of life with effective disease-modifying
antirheumatic drugs: evidence from randomized controlled trials. [2008]
The multi-faceted assessment of independence in patients with rheumatoid
arthritis: preliminary validation from the ATTAIN study. [2008]
An index of only patient-reported outcome measures, routine assessment of patient
index data 3 (RAPID3), in two abatacept clinical trials: similar results to
disease activity score (DAS28) and other RAPID indices that include
physician-reported measures. [2008]
Improved health-related quality of life with effective disease-modifying
antirheumatic drugs: evidence from randomized controlled trials. [2007]
Abatacept inhibits progression of structural damage in rheumatoid arthritis:
results from the long-term extension of the AIM trial. [2008]
Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis. [2007]
Efficacy results from pivotal clinical trials with abatacept. [2007]
Efficacy and safety of the selective co-stimulation modulator abatacept following
2 years of treatment in patients with rheumatoid arthritis and an inadequate
response to anti-tumour necrosis factor therapy. [2008]
Responsiveness of patient reported outcomes including fatigue, sleep quality,
activity limitation, and quality of life following treatment with abatacept for
rheumatoid arthritis. [2008]
Abatacept: a novel therapy approved for the treatment of patients with rheumatoid
arthritis. [2007]
Surveillance of the eye and vision in clinical trials of CP-675,206 for
metastatic melanoma. [2007]
Item response theory methods can improve the measurement of physical function by
combining the modified health assessment questionnaire and the SF-36 physical
function scale. [2007]
Determining the minimal clinically important differences in activity, fatigue,
and sleep quality in patients with rheumatoid arthritis. [2007]
Reduction of inflammatory biomarker response by abatacept in treatment of
rheumatoid arthritis. [2006]
Safety of the selective costimulation modulator abatacept in rheumatoid arthritis
patients receiving background biologic and nonbiologic disease-modifying
antirheumatic drugs: A one-year randomized, placebo-controlled study. [2006]
Are American College of Rheumatology 50% response criteria superior to 20%
criteria in distinguishing active aggressive treatment in rheumatoid arthritis
clinical trials reported since 1997? A meta-analysis of discriminant capacities. [2006]
Abatacept: a costimulatory inhibitor for treatment of rheumatoid arthritis. [2005]
Projecting long-term graft and patient survival after transplantation. [2014]
Remission induction comparing infliximab and high-dose intravenous steroid,
followed by treat-to-target: a double-blind, randomised, controlled trial in
new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). [2014]
Biological therapies in rheumatic diseases. [2013]
Effect of abatacept on immunogenicity of vaccines in individuals with type 1
diabetes. [2013]
Head-to-head comparison of subcutaneous abatacept versus adalimumab for
rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. [2014]
Challenges and opportunities in SLE clinical trials. [2013]
Drug therapy in undifferentiated arthritis: a systematic literature review. [2013]
Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on
health-related quality of life in patients with active rheumatoid arthritis:
analyses of patient-reported outcomes from a randomized, double-blind,
placebo-controlled trial. [2013]
Changes in use of disease-modifying antirheumatic drugs for rheumatoid arthritis
in the United States during 1983-2009. [2013]
Efficacy of biological agents in juvenile idiopathic arthritis: a systematic
review using indirect comparisons. [2013]
Head-to-head comparison of subcutaneous abatacept versus adalimumab for
rheumatoid arthritis: findings of a phase IIIb, multinational, prospective,
randomized study. [2013]
Immunogenicity, safety, and efficacy of abatacept administered subcutaneously
with or without background methotrexate in patients with rheumatoid arthritis:
results from a phase III, international, multicenter, parallel-arm, open-label
study. [2013]
The 'Switch' study protocol: a randomised-controlled trial of switching to an
alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab
in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor
drug. [2014]
Lessons from type 1 diabetes for understanding natural history and prevention of
autoimmune disease. [2014]
Are sample sizes of randomized clinical trials in rheumatoid arthritis too large? [2014]
|